Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of Lipopolysaccharide-Induced Interleukin 8 in Human Adenocarcinoma Cell Line HT-29 by Spore Probiotics: B. coagulans and B. subtilis (natto).
|
27785697 |
2017 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Interleukin 8 (IL-8) mediates the angiogenesis of tumors arising from Ras mutations, which are present in about 90% of pancreatic adenocarcinomas.
|
27749658 |
2017 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Our findings suggest that IL-8 expression is associated with certain clinicopathological features including age and is a potent prognostic marker in lung adenocarcinoma, especially in oncogenic KRAS-driven adenocarcinoma.
|
24577055 |
2014 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Brachyury mRNA expression was significantly inversely correlated to E-cadherin expression (P = 0.0252) and positively correlated to IL-8 protein (P = 0.0241) and to Slug protein (P = 0.0243) in adenocarcinoma tissues.
|
23456319 |
2013 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
Higher IL-8 production was found for both SCC and AdC compared to controls.
|
23441128 |
2013 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Clinical analysis indicated a borderline positive association of IL-8 -251T allele among adenocarcinoma patients (P=0.003).
|
23831257 |
2013 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
These results indicate that activating mutations of KRAS or EGFR upregulate IL-8 expression in NSCLC; IL-8 is highly expressed in NSCLCs from males, smokers, elderly patients, NSCLCs with pleural involvement, and KRAS-mutated adenocarcinomas; and IL-8 plays a role in cell growth and migration in oncogenic KRAS-driven NSCLC.
|
21544811 |
2012 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
BEFREE |
In this study, we provide evidence that interleukin 8 (IL8)-CXCR2-P53 (TP53) signaling pathway keeps the NE cells of benign prostate and adenocarcinoma in a quiescent state normally.
|
22389383 |
2012 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
DNA promoter methylation status and protein expression of interleukin-8 in human colorectal adenocarcinomas.
|
22108905 |
2012 |
Adenocarcinoma
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Interleukin-8-251A/T polymorphism and Helicobacter pylori infection influence risk for the development of gastric cardiac adenocarcinoma in a high-incidence area of China.
|
20300863 |
2010 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
CXCL8 expression correlated with nuclear beta-catenin localization in epithelial cells of adenomas, but was associated with endothelial cells and neutrophils in the adenocarcinomas.
|
19173296 |
2009 |
Adenocarcinoma
|
0.400 |
Biomarker
|
group |
CTD_human |
Interleukin-8 increases vascular endothelial growth factor and neuropilin expression and stimulates ERK activation in human pancreatic cancer.
|
18307536 |
2008 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Patients with the highest IL-8 expression were those with Barrett's dysplasia and adenocarcinoma (P<.001).
|
17576892 |
2007 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
LHGDN |
Differential regulation of RANTES and IL-8 expression in lung adenocarcinoma cells.
|
17207890 |
2007 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Pretreatment of HT29-D4 epithelial adenocarcinoma colic cells with des-IGF-1 upregulated TNF alpha-mediated activation of IL-8 expression at different levels (protein, mRNA, and hnRNA).
|
12767906 |
2003 |
Adenocarcinoma
|
0.400 |
AlteredExpression
|
group |
BEFREE |
In this study we evaluated, for the first time, IL-8 messenger RNA (mRNA) expression in non-small-cell lung cancer (NSCLC), using real-time quantitative reverse-transcription-polymerase chain reaction, and correlated IL-8 mRNA expression in tumor and nontumor lung samples from 58 patients with NSCLC (29 with squamous cell carcinoma and 29 with adenocarcinoma, of whom 20 had Stage I, 10 had Stage II, and 28 had Stage III disease) with these patients' clinicopathologic characteristics, angiogenesis, and outcome.
|
11069840 |
2000 |